Ten Thousand Points of Light: Heterogeneity Among the Stars of NASH Fibrosis

HepatologyVolume 74, Issue 2 p. 543-546 Editorial Ten Thousand Points of Light: Heterogeneity Among the Stars of NASH Fibrosis James Carter BA, James Carter BA Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NYSearch for more papers by this authorShuang Wang PhD, Shuang Wang PhD Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NYSearch for more papers by this authorScott L. Friedman M.D., Corresponding Author Scott L. Friedman M.D. scott.friedman@mssm.edu Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO: Scott L. Friedman, M.D. Division of Liver Diseases Icahn School of Medicine at Mount Sinai Box 1123 1425 Madison Ave, Room 1170C New York, NY 10025 E-mail: scott.friedman@mssm.edu Tel.: +212-659-9501Search for more papers by this author James Carter BA, James Carter BA Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NYSearch for more papers by this authorShuang Wang PhD, Shuang Wang PhD Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NYSearch for more papers by this authorScott L. Friedman M.D., Corresponding Author Scott L. Friedman M.D. scott.friedman@mssm.edu Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO: Scott L. Friedman, M.D. Division of Liver Diseases Icahn School of Medicine at Mount Sinai Box 1123 1425 Madison Ave, Room 1170C New York, NY 10025 E-mail: scott.friedman@mssm.edu Tel.: +212-659-9501Search for more papers by this author First published: 16 March 2021 https://doi.org/10.1002/hep.31807Citations: 1 Supported by the National Institutes of Health (T32 GM007280 and T32GM062754 to J.C., and 1R01 DK56621 and 1R01 DK128289 to S.L.F.) and the American Gastroenterology Association (AGA2020-13-03 to S.W.). Potential conflict of interest: Dr. Friedman consults and owns stock in Blade, Escient, Galmed, Glympse, Hepgene, Morphic, North Sea, Scholar Rock, and Surrozen. He consults for 89BIO, Amgen, Axcella, Bristol-Meyers Squibb, Can-Fite, ChemomAb, Forbion, Foresite, Gordian, Glycotest, In sitro, Novartis, Ono, and Pfizer. He owns stock in Galectin, Genfit, Intercept, Madrigal, Group K, Lifemax, Metacrine, and Nimbus. See Article on Page 667 Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume74, Issue2August 2021Pages 543-546 RelatedInformation